More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics

The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patie...

Descripción completa

Detalles Bibliográficos
Autor principal: Bernards, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980300/
https://www.ncbi.nlm.nih.gov/pubmed/36750414
http://dx.doi.org/10.1002/1878-0261.13391
_version_ 1784899885611352064
author Bernards, René
author_facet Bernards, René
author_sort Bernards, René
collection PubMed
description The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care.
format Online
Article
Text
id pubmed-9980300
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99803002023-03-03 More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics Bernards, René Mol Oncol Viewpoint The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care. John Wiley and Sons Inc. 2023-02-15 /pmc/articles/PMC9980300/ /pubmed/36750414 http://dx.doi.org/10.1002/1878-0261.13391 Text en © 2023 The Author. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Viewpoint
Bernards, René
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
title More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
title_full More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
title_fullStr More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
title_full_unstemmed More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
title_short More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
title_sort more may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980300/
https://www.ncbi.nlm.nih.gov/pubmed/36750414
http://dx.doi.org/10.1002/1878-0261.13391
work_keys_str_mv AT bernardsrene moremaynotbebetterreconsideringearlyclinicaltrialdesignintheeraoftargetedcancertherapeutics

Ejemplares similares